F
G
Coronavirus (COVID-19) Patient/Carer Notice

Shared Vision
Education

Case Study

45-year-old woman with increasing blurred vision and photophobia

Dr Nima Pakrou

18/07/2018

History/Presentation

A 45-year-old female was referred for increasing blurred vision and photophobia in her right eye over the preceding week, with reduced foreign-body sensation. She had previously been referred to an ophthalmologist with similar symptoms.

RVA: 6/7.5
LVA: 6/5

Figure 1: Slit lamp image of right eye showing small subepithelial infiltrates.

 

  • What else is important to ask this patient?
    • Recent cold/flu-like illness
    • Recent or past history of cold sores
    • History of chicken pox and/or shingles (punctate keratitis and small pseudodendrites can occur up to 1/12 after V1 shingles)
  • What treatment has previously been given?
    • Patient unsure (?steroids, ?Zovirax, ?tablets)
    • Request notes from other treating ophthalmologist
  • What can you see?
    • Subepithelial haze/nummular keratitis
    • 1+ AC cells
  • What are the differential diagnoses?
    • HSV kerato(uveitis)
    • Adenoviral/other viral keratitis (e.g. Epstein-Barr virus)
    • Varicella zoster keratitis (history or recent shingles)
    • Bacterial/fungal (usually more fluffy with other red flags in patient history)
  • What other examination/tests would you like to do?
    • Fluorescein staining/eye drops
    • Corneal sensation (important in herpetic disease)
    • Iris atrophy/transillumination (sectoral versus patchy) – HSV/VZV
    • Always check the fundus for retinal/choroidal/vascular abnormalities

 

Figure 2: Fluorescein stain (right eye) confirms the presence of small epithelial defects

The patient reveals a history of cold sores, including a recent flare-up. Approximately 12 months ago, she had seen another ophthalmologist for the same symptoms and the patient notes confirmed she had been treated with Maxidex and Zovirax.

Diagnosis

Given her history and presence of small epithelial defects (but not dendrites), it is highly likely this patient has herpes simplex virus (HSV) keratouveitis.

Treatment

  • Start Maxidex (dexamethasone) and taper slowly over 4 weeks (qid, tds, bd, daily)
  • Zovirax 3% (aciclovir) ointment cover may decrease the risk of dendritic ulcer developing
    • Consider stopping Zovirax after 2 weeks as the risk of epithelial HSV is very low in true herpetic keratitis. Some clinicians only use topical steroids, but it’s probably safer to cover with Zovirax ointment for initial 1-2 weeks.

Oral famciclovir was discussed with the patient as an alternative anti-viral option. Compared to topical Zovirax, oral famciclovir offers quicker resolution of symptoms, less corneal toxicity and some added benefit if uveitis is present. However, the cost is often prohibitive for patients because it is not listed on the PBS for HSV.

Progress

2 weeks after presentation

Figure 3: Slit lamp examination of right eye 2 weeks after beginning treatment. No epithelial defects evident.

4 weeks after presentation

Figure 4: Slit lamp examination of right eye 4 weeks after initial presentation.

Figure 5: Fluorescein stain confirms the recurrence of small right epithelial defects. The patient admitted to stopping treatment after 3 weeks.

 

Managing HSV recurrence

  • Re-commenced topical Zovirax tds
  • Initiated Flarex eye drops (fluoromethalone) qid
  • Stressed importance of slow taper over 6–8 weeks
    • Flarex qid 1/52 with tds Zovirax
    • Flarex tds 1/52 with tds Zovirax
    • Flarex bd 1/52 with bd Zovirax
    • Flarex daily 2 weeks with daily Zovirax
    • Flarex alternate days 2 weeks with alternate day Zovirax

The patient was asked to return for a review in 1–2 weeks and again 2 weeks after stopping treatment (or ASAP if symptoms are worsening).

HSV keratitis nomenclature

  1. Epithelium
    • HSV epithelial keratitis (dendritic epithelial ulcer or geographic epithelial ulcer)
  2. Stroma
    • HSV stromal keratitis without ulceration (non-necrotising keratitis, interstitial keratitis, immune stromal keratitis)
    • HSV stromal keratitis with ulceration (necrotising keratitis)
  3. Endothelium
    • HSV endothelial keratitis (disciform keratitis)

 

DENDRITIC ULCER

dendritic-ulcer-nima dendritic-ulcer-nima-2

 

HERPETIC KERATOUVEITIS

herpetic-keratouveitis-nima

 

RECURRENT INTERSTITIAL KERATITIS + NEW DISCIFORM

recurrent-interstitial-keratitis_nima

 

ENDOTHELIAL/DISCIFORM KERATITIS

endothelial-keratitis_nima

Figure 6: Area of localised corneal oedema and a few keratic precipitates, consistent with a diagnosis of disciform keratitis. AC inflammation if minimal. If there is moderate AC inflammation (AC cells >1+), then a diagnosis of keratouveitis is likely.

endothelial-keratitis_nima-3

 

HERPETIC SCARS

herpetic-scars 1herpetic-scars 2

 

GEOGRAPHIC ATROPHY

geographic-atrophy

 

HSV keratitis treatment protocol

Epithelial disease only

Topical corticosteroids should be avoided in the initial management of HSV epithelial keratitis.

  1. Dendritic ulcer
    • Debride/debulk: LA-soaked cotton wool rolled over lesion
    • Topical acyclovir: 5 times per day day 7/7, tds 7/7 OR
    • Oral aciclovir, valaciclovir, famciclovir: 7–10 days then lower dose
  2. Geographic ulcer
    • Topical aciclovir: 5 times per day until healing then tds 7/7
      • Watch for toxicity/non healing/worsening, which requires oral Rx
      • Intensive gel lubricants (e.g. Genteal Tears)
    • Oral antivirals (maximum dose): 2–3/52 (preferred as less corneal toxicity) but are expensive 

Stromal disease

  1. Without epithelial ulceration
    • Topical steroids: 4–6 times per day, tapering quickly at first and then more slowly (e.g. by 1 drop weekly for first 3­–4 weeks then every second week for next 4–6 weeks)
    • May need 6–12 weeks of treatment, depending on response and history
    • Oral/topical antiviral cover: lower/prophylactic oral dose of acyclovir or famciclovir or bd–tds topical Zovirax cover
  2. With epithelial ulceration
    • Antiviral cover: topical or oral using therapeutic (higher) dose
    • Topical steroids: lower dose (e.g. bd) until ulcer heals then increase as necessary OR
    • Withhold steroid for first 24–36 hours of antiviral therapy before commencing lower dose and increasing once ulcer heals
    • Taper steroids as above or based on disease response

Endothelial keratitis/disciform keratitis

  • Responds more quickly than stromal keratitis
  • Initiate therapeutic dose of antivirals for 7­–10 days, then drop to prophylactic dose while on steroids
  • Topical steroids 4–6 times per day for 7­–10 days, then taper over 3­–4 weeks based on response

If AC inflammation is severe, steroids may need to be administered more frequently.

HSV long-term oral prophylaxis

Prophylaxis is considered in patients with:

  • >1 recurrence within 12 months
  • Scar/vascularisation getting close to visual axis
  • Pre/post-operative patient with a history of HSV keratitis (e.g. undergoing corneal graft, refractive other ocular surgery)
  • Immunocompromised (e.g. on chemotherapy).

Key message:

Herpes viruses, including HSV1, HSV2 and VSV, can all affect the eye. The possible diagnosis of such conditions should always be kept in the back of the mind in any patient presenting with corneal inflammatory changes (oedema, infiltrates, epithelial defect) and/or uveitis. Any patient with suspected corneal herpetic disease must have a dilated exam to look for intraocular involvement.

Dr Nima Pakrou is an experienced ophthalmologist with expertise across a range of eye conditions. His subspecialty areas include medical retinal diseases, cataracts, intraocular inflammation and oculoplastics. He practises at Vision Eye Institute Footscray.

IMPORTANT: If you are concerned about your eyes and require an urgent consultation, DO NOT use this form. Please call one of our clinics during office hours or contact your nearest emergency department.

coloured spectrum bar